A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein

Rheumatology (United Kingdom)

Volumn 52, Issue 8, 2013, Pages 1467-1476

  Moncrieffe, Halima ^a   Ursu, Simona ^a   Holzinger, Dirk ^b,c   Patrick, Fiona ^a   Kassoumeri, Laura ^a   Wade, Angie ^a   Roth, Johannes ^b   Wedderburn, Lucy R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Biomarker; CHARM study; Disease outcome; Juvenile idiopathic arthritis; Methotrexate; Paediatric; Response to treatment; Rheumatology

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 6; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 14; MULTIDRUG RESISTANCE PROTEIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; DISEASE ACTIVITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; IMMUNOASSAY; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

BIOMARKER; CHARM STUDY; DISEASE OUTCOME; JUVENILE IDIOPATHIC ARTHRITIS; METHOTREXATE; PAEDIATRIC; RESPONSE TO TREATMENT; RHEUMATOLOGY;

ADMINISTRATION, ORAL; ADOLESCENT; ANALYSIS OF VARIANCE; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CALGRANULIN A; CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; METHOTREXATE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880578156     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket152     Document Type: Article

References (36)

1. Foster HE, Marshall N, Myers A et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
2. Nordal E, Zak M, Aalto K et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63:2809-18.
3. Minden K, Niewerth M, Zink A et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012;51:1407-15.
4. Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
5. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
6. Ruperto N, Lovell DJ, Li T et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res 2010;62:1542-51.
7. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
8. DeWitt EM, Kimura Y, Beukelman T et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012;64:1001-10.
9. Wallace CA, Giannini EH, Spalding SJ et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
10. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
11. Klassen TP, Hartling L, Craig JC et al. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med 2008;5:e172.
12. Albers HM, Wessels JA, van der Straaten RJ et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:46-51.
13. Bartoli M, Taro M, Magni-Manzoni S et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67: 370-4.
14. Moncrieffe H, Hinks A, Ursu S et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet Genomics 2010;20:665-76.
15. Hinks A, Moncrieffe H, Martin P et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis 2011;70: 1395-400.
16. Mulligan K, Etheridge A, Kassoumeri L et al. Do mothers and fathers hold similar views about their child's arthritis? Arthritis Rheum 2009;61:1712-8.
17. Foell D, Wulffraat N, Wedderburn LR et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.
18. Gerss J, Roth J, Holzinger D et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 2012;71:1991-7.
19. Frosch M, Ahlmann M, Vogl T et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:883-91.
20. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
21. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
22. Nugent J, Ruperto N, Grainger J et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19(4 Suppl 23):S163-7.
23. Consolaro A, Ruperto N, Bazso A et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61: 658-66.
24. Frosch M, Strey A, Vogl T et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticularonset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43:628-37.
25. De Jager W, Hoppenreijs EP, Wulffraat NM et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007;66:589-98.
26. Holzinger D, Frosch M, Kastrup A et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012;71:974-80.
27. Wulffraat NM, Haas PJ, Frosch M et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis 2003;62:236-241.
28. De Jager W, Bourcier K, Rijkers GT et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009;10:52.
29. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58: 859-68.
30. Shenoi S, Wallace CA. Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Rep 2010;12:80-6.
31. Bulatovic M, Heijstek MW, Van Dijkhuizen EH et al. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012;71:1484-9.
32. Wessels JA, Van der Kooij SM, Le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
33. Fransen J, Kooloos WM, Wessels JA et al. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 2012; 13:1087-94.
34. Iwamoto N, Kawakami A, Fujikawa K et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol 2009;19:488-92.
35. Hyrich KL, Lal SD, Foster HE et al. Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology 2010;49:116-22.
36. Minden K, Niewerth M, Zink A et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012;51: 1407-15.